Apremilast and Moderate to Severe Chronic Hand Dermatitis
Status:
Terminated
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
Investigators have designed a pilot study involving chronic hand dermatitis (CHD) patients
who attend the dermatology clinic at the George Washington Medical Faculty Associates (GW
MFA) in order to assess the efficacy and safety of apremilast treatment for the treatment of
moderate to severe CHD.